ALLHAT

ALLHAT
Name	ALLHAT
Full name	Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
Acronym	ALLHAT
Phase	III
Types	randomized, multicenter, double-blind
Start date	1994
Completion date	2002
Investigators	National Heart, Lung, and Blood Institute, Duke University, Johns Hopkins University
Participants	42,418
Conditions	Hypertension
Interventions	ACE inhibitors, Calcium channel blockers, Diuretics

ALLHAT

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial was a large, multicenter, randomized clinical trial funded by the National Heart, Lung, and Blood Institute that compared antihypertensive strategies to prevent cardiovascular events. It enrolled adult participants across multiple sites in the United States, Canada, Puerto Rico, and the United Kingdom, and produced influential evidence that informed major cardiovascular organizations and guideline panels. The trial's scale and pragmatic design engaged academic centers, community clinics, and federal agencies.

Background and rationale

ALLHAT was conceived amid debates among leaders at the National Heart, Lung, and Blood Institute, investigators at Duke University School of Medicine, and faculty at Johns Hopkins University School of Medicine about optimal first-line therapy for hypertension. Policymakers from the Department of Health and Human Services and advisory bodies such as the Institute of Medicine sought comparative-effectiveness evidence to inform recommendations by organizations including the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Major stakeholders like Merck & Co., Pfizer, and other pharmaceutical firms observed that class-based differences among diuretics, angiotensin-converting enzyme inhibitors, calcium channel blockers, and beta blockers lacked definitive large-scale randomized comparison. Prior landmark trials such as Framingham Heart Study, Multiple Risk Factor Intervention Trial, and Systolic Hypertension in the Elderly Program highlighted the need for pragmatic outcome-driven research to reduce rates of myocardial infarction, stroke, and heart failure.

Study design and methodology

ALLHAT was a randomized, double-blind, active-controlled trial coordinated by the National Heart, Lung, and Blood Institute with field centers at institutions like University of Texas Southwestern Medical Center, University of Minnesota, and University of California, San Francisco. The protocol enrolled 42,418 participants aged 55 or older with hypertension and at least one additional cardiovascular risk factor, following ethical oversight by Institutional Review Boards at Duke University, Johns Hopkins University, and participating hospitals. Randomization allocated participants to an open-label but blinded endpoint comparison of a thiazide-type diuretic (chlorthalidone), an angiotensin-converting enzyme inhibitor (lisinopril), or a calcium channel blocker (amlodipine); a lipid-lowering substudy randomized to pravastatin. Primary outcomes and adjudication involved committees with members from Mayo Clinic, Cleveland Clinic, Massachusetts General Hospital, and international collaborators. The statistical plan employed time-to-event analyses, Kaplan–Meier estimates, and Cox proportional hazards models developed with input from biostatisticians at Harvard School of Public Health and Columbia University.

Results and primary outcomes

The primary composite outcome—fatal coronary heart disease or nonfatal myocardial infarction—showed no superiority of lisinopril or amlodipine compared with chlorthalidone. ALLHAT reported similar rates of the primary outcome across arms, while secondary endpoints revealed differences: rates of heart failure were higher with lisinopril and amlodipine compared with chlorthalidone, whereas rates of stroke varied by subgroup. Major presentations occurred at meetings of the American Heart Association and results were published in The New England Journal of Medicine and disseminated by the Centers for Disease Control and Prevention. Outcomes influenced statements by the World Health Organization and national guideline panels including the Joint National Committee.

Secondary analyses and subgroup findings

Prespecified and post-hoc subgroup analyses examined differential effects by race, age, sex, and comorbidities, with notable findings in participants self-identified as Black or African American—where chlorthalidone reduced stroke and clinical outcomes more than lisinopril—informing recommendations from the National Medical Association and the American College of Physicians. Secondary analyses evaluated renal outcomes, metabolic effects such as new-onset diabetes mellitus incidence, lipid changes in the pravastatin substudy, and absolute risk reductions stratified by baseline risk estimated from models used by Framingham Heart Study and the European SCORE project. Detailed subgroup papers involved authors affiliated with Vanderbilt University Medical Center, Stanford University School of Medicine, and Yale School of Medicine.

Controversies and critiques

ALLHAT generated debate among leaders at American College of Cardiology conferences, commentators in The Lancet, and analysts at The New York Times about interpretation and generalizability. Critics from academic centers such as Oxford University and University College London questioned choice of chlorthalidone dose, differential blood pressure control across arms, and potential biases related to trial conduct at diverse community clinics and Veterans Affairs sites. Methodologists from Johns Hopkins Bloomberg School of Public Health and London School of Hygiene & Tropical Medicine raised concerns regarding subgroup multiplicity and post-hoc analyses. Pharmaceutical stakeholders including AstraZeneca and Novartis highlighted implications for calcium channel blocker and ACE inhibitor markets; debates transpired at policy forums convened by the Food and Drug Administration and in statements by the World Bank and Organisation for Economic Co-operation and Development.

Impact on guidelines and clinical practice

ALLHAT influenced updates to hypertension guidelines from the Joint National Committee, the American College of Cardiology, the American Heart Association, and the European Society of Cardiology/European Society of Hypertension, leading to reinforced recommendations for thiazide-type diuretics as first-line therapy in many patients. Clinical adoption was observed across settings including Veterans Health Administration clinics, community health centers, and academic medical centers such as Mayo Clinic and Cleveland Clinic. Health policy-makers at Centers for Medicare & Medicaid Services and formulary committees at institutions like Kaiser Permanente used ALLHAT data to inform drug-selection and cost-effectiveness analyses. Subsequent trials and systematic reviews by groups including Cochrane and meta-analyses conducted at Johns Hopkins have continued to reference ALLHAT in comparative-effectiveness literature.

Category:Clinical trials